The agreement with Poseida is by far the larger of the two, with Roche paying $110 million upfront to license rights to off-the-shelf CAR-T therapies aimed at haematological cancers, including one ...

1 Day RHHBY 2.56% DJIA 0.77% S&P 500 1.04% Health Care/Life Sciences 0.10% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Fenebrutinib is currently the only reversible, non-covalent inhibitor of BTK in late-stage development, which Roche maintains could translate into a cleaner side effect profile than other drugs in ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Jackie Reeve Jackie Reeve is a writer covering all things bedding.

Kate St. John’s ongoing nightmare with Arizona’s Motor Vehicle Division is finally over, and she credits On Your Side for making it happen.

If you watched this year's iPhone launch event, you could've been forgiven for thinking that the iPhone XS is the most underwhelming 'S' upgrade in the iPhone's history. Apple spent surprisingly ...

If you watched this year's iPhone launch event, you could've been forgiven for thinking that the iPhone XS is the most underwhelming 'S' upgrade in the iPhone's history. Apple spent surprisingly ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...

A daytime morning “chatfest” featuring a team of dynamic and diverse women, discussing the most exciting events of the day.